FDA
1 min.Read

VySpine Announces FDA Clearance for LumiVy Lumbar IBF with NanoVy Ti

VySpine, a spine innovation leader using differentiated materials and designs, announced today that it has received 510(k) clearance from the FDA for its LumiVy NanoVy Ti Lumbar IBF System which is indicated for intervertebral body fusion for use at either one level or two contiguous levels in the lumbar spine, from L2 to S1, for the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis.

The LumiVy NanoVy Ti Lumbar IBF System features VySpine’s NanoVy Ti coating technology in partnership with Implant Surfaces. NanoVy Ti is a titanium coating that is mere nanometers thick, adhered to a PEEK LumiVy implant. The NanoVy Ti coating is engineered to facilitate direct osteoblast attachment to the entire surface of the LumiVy implant.

The high adhesion and impact resistant NanoVy Ti coating bonds intimately to the PEEK structure, and has been shown to increase expulsion resistance of the LumiVy implant. Furthermore, the NanoVy Ti technology does this without compromising the radiolucency, or favorable modulus of elasticity, of the PEEK material.

The LumiVy NanoVy Ti Lumbar IBF System is a robust, yet elegantly simple system. It is offered in a vast array of footprints for nearly any lumbar interbody approach. Additionally, it is available in a range of sizes, heights, and lordotic angles.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

0
Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

0
EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

0
The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

0
Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

0
Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.

About us

Medical Device News Magazine

Welcome to Medical Device News Magazine, a digital publication providing up to the minute medical device and biotechnology news.

Need to know more?

Contact us

Navigation

Florida, New York, No. Carolina
United States
Phone Number: 1.561.316.3330